

Approved by PCI and Affiliated to Osmania University, Hyderabad.
Accredited by NBA-UG Program, NAAC A+ Grade.
Recognition of College under Section 2(f) of the UGC Act 1956,
UGC Autonomous Institution



M.Pharmacy (Pharmacology) II Semester (PCI) (Main) Examination Jul/Aug 2024

Subject& Code: Pharmacological and Toxicological Screening Methods-II & MPL202T Time: 3 Hours

Max.Marks: 75


Note: Answer any FIVE questions. All questions carry equal marks.

Q.No.	Question	Marks	CO	BL
1	a) Explain the role of toxicology in drug development and describe the	8	1	2
	types of toxicology.	A SHARE		
	b) What are the OECD principles of Good Laboratory Practice (GLP) and	7	3	1
	why are they important in drug development?			
2	a) Compare and contrast acute, sub-acute, and chronic toxicity studies for	8	1	2
	oral routes as per OECD guidelines.			١.
	b) Analyze the methodologies and regulatory requirements for acute eye	7	1	4
	irritation studies as per OECD guidelines.			
3	a) What is reproductive toxicity? Describe the study design and	8	2	1
	significance of male reproductive toxicity studies.			
	b) Compare and contrast different genotoxicity studies.	7	2	2
4	a) Define IND and discuss the significance and industry perspective of	8	4	1
	IND enabling studies.			
	b) What are Tier 1 safety pharmacology studies, and why are evaluations	7	4	2
	of CVS, CNS, and respiratory systems important in drug development?	1		
5	a) Define toxicokinetics and explain its role in preclinical studies. How	8	5	1,2
	does toxicokinetic evaluation differ from pharmacokinetic evaluation?			
A	b) Propose alternative methods to animal toxicity testing and evaluate its	7	5	6
	advantages and limitations.			
6	a) Discuss about dermal toxicity studies.	7	2	2
	b) Explain in vivo carcinogenicity studies and explain their role in	1		
	regulatory toxicology. Which animals are commonly used in these	8	2	2
	studies?	, l		
7	a) Evaluate the procedures and importance of dermal irritation studies as	8	1	5
,	per OECD guidelines.		0.4	
	b) Examine the ethical concerns of safety pharmacology studies. How	7	1	4
	can risks to animals be reduced while ensuring reliable data for	E"	Įř.	
	regulatory approval?			1
8	a) What are the key regulatory guidelines provided by ICH for	8	1	1
	conducting toxicity studies?	. 54	à.	1
	b) Discuss the applications of toxicokinetics.	7	5	2

Code. No.M7082423



Approved by PCI and Affiliated to Osmania University, Hyderabad. Accredited by NBA-UG Program, NAAC A+ Grade. Recognition of College under Section 2(f) of the UGC Act 1956, UGC Autonomous Institution



M.Pharmacy (Pharmacology) II Semester (PCI) (Main) Examination Jul/Aug 2024


Subject & Code: PRINCIPLES OF DRUG DISCOVERY & MPL 203T

Time: 3 Hours Max.Marks: 75

Note: Answer any FIVE questions. All questions carry equal marks.

Q.No.	Question		CO	BL
1	a) Explain lead identification and optimization	10	3	2
	b) Write the role of protein microarrays in target discovery	5	3	3
2	a) Discuss the Economics of drug discovery	10	3	2
	b) Discuss the use of X-ray crystallography in protein structure	5	3	2
	prediction			
3	a) Explain Insilco lead discovery techniques	8	4	2
	b) Discuss structure based approaches in rational drug design	7	4	2
4	a)Outline motifs and folds in protein structure	5	2	1
	b) Explain various steps in threading modelling	10	2	2
5	a) Describe the role of combinatorial chemistry lead identification	5	4	2
	b) Describe docking based screening	5	4	2
	c) Explain process manual docking	5	4	2
6	a) Compare and contrast between SAR and QSAR	10	5	4
	b) Outline rigid docking	5	5	4
7	a) Appraise the value of regression analysis in drug discovery	5	4	5
	b) Assess the difference between SAR and QSAR	10	4	5
8	a) Formulate rationale of prodrug design	8	1	6
	b) Design sustained drug action	7	1	6

Code. No. M7082424



Approved by PCI and Affiliated to Osmania University, Hyderabad.
Accredited by NBA-UG Program, NAAC A+ Grade.
Recognition of College under Section 2(f) of the UGC Act 1956,
UGC Autonomous Institution



M.Pharmacy (Pharmacology) II Semester (PCI) (Main) Examination Jul/Aug 2024


Subject & Code: CLINICAL RESEARCH AND PHARMACOVIGILANCE & MPL 204 T

Time: 3 Hours Max.Marks: 75

Note: Answer any FIVE questions. All questions carry equal marks.

Q.No.	Question	Marks	CO	BL
1	a) Explain the principles of ICH-GCP guidelines.	8	1	2
•	b) Describe the Schedule Y guidelines in clinical trials.	8		2
2	a) Write the composition and responsibilities of IRB.	0 7	3	3
	b) Explain the roles and responsibilities of Clinical Investigator.	8		2
3	a) Discuss the various steps involved in preparing a protocol.b) Write in detail about international classification of diseases.	7	1	3
4	What are the differences in Indian and Global pharmacovigilance	15	5	4
•	requirements?	8	6	1
5	a) Define ADR. Classify with examples.	7	0	2
	b) Write about the predictability and preventability assessment of ADR.	/		
6	Write a note on	0	2	3
	a) Observational studies	8	2	3
	b) Spontaneous reporting system	7	4	_
7	a) Explain the methods of safety monitoring in clinical trails	8	4	2
'	b) What are the various statistical methods for evaluating	7		3
	medication safety data.			
8	Discuss the following			
	a) Declaration of Helsinki	5		
4	b) Vaccine safety surveillance	5	1	3
	c) Pharmacoeconomics	5		





M.Pharmacy (Pharmacology) II Semester (PCI) (Main) Examination Jul/Aug 2024

Subject& Code: ADVANCED PHARMACOLOGY-II & MPL201T

Max.Marks: 75 Time: 3 Hours

PART- A					
Note: Answer any FIVE questions. All questions carry equal marks.			Marks	CO	BL
Q.No.	Questio	n a to the Post the	Viarks	2,3	3
1	a)	Write brief notes on pathophysiology of tuberculosis. Explain the		2,5	
		treatment of tuberculosis according to Revised National			
		Tuberculosis Control Programme (RNTCP) guidelines.	8	2	2
	1-1	What are beta lactam antibiotics? Explain the pharmacology of			
	(0	any one beta lactam antibiotics.			
2	a)	Classify anti-cancer drugs. Explain about MOA,	8	3	3
2	(")	pharmacokinetics and therapeutic uses of Pyrimidine antagonists			
				_	
	b)	Explain the role of free radicals in the neurodegenerative disease	7	5	2
		like cancer			_
3	a)	Write down the applications of chronopharmacology in	7	4	2
		cardiovascular diseases.			
		Fundam Abanda of Proton Pump	8	4	3
	(b)	Classify Anti-ulcer drugs. Explain the role of Proton Pump		١.	
		Inhibitors in the treatment of Peptic-ulcer Write brief notes on factors mediating to cause bronchial asthma	8	3	3
4	a)	and role of sympathomiment treatment of asthma?			
	b)	Define immunostimulants Explain the role immunostimulants in			
		improving immunity with examples.	7	3	1
5	a)	Classify anti-fungal drugs and note down different types of	7	2	3
		fungal infection.			
		and the state of t	8	2	2
	b)		8	2	2
		one macrolide antibiotic? Explain the role of insulin in the regulation of glucose level and	7	1	2
6	a)	its metabolic functions	'		
		ns membere functions			
	(d	Classify oral hypoglycemic agents. Write brief notes on	8	1	3
		pharmacology of biguanides			
7	a)		7	1	3
				,	
	b)		8	1	3
		inhibitors	7	3	3
8	a)	Write notes on drugs used in the treatment of helminthiasis.	'	3	٦
	b)	Classify immunosuppressants. Explain MOA, Adverse effects	8	3	3
	0)	and therapeutic uses of Calcineurin inhibitors			
		and merapedite does of emericanity			
